ホームページへ

ページ2 - 最高の甲状腺機能検査医師 - トップ87名の医師

コンテンツはBookimed編集ポリシーを満たし、以下により医学的にレビューされています

Fahad Mawlood

Bulent Hacimeoglu

  • 4.9 優秀 55 レビュー
  • 26年の経験
  • 認定:
  • トルコ, イスタンブール, Valued Med Hub Hospitals
  • Education and Expertise

    (1994 – 2000) - GATA Faculty of Medicine Ankara

    (2003 – 2007) - GATA Medical Faculty Pediatrics and Diseases

    (2008 -2011) - Ankara University Pediatric Endocrinology

    (03.03.2014) - Associate Professorship, Pediatric Endocrinology

    (17.07.2019) - Professorship, Istinye University Faculty of Medicine

     

    Experience

    (2001 – 2003) - Special Forces Command/Ankara

    (2007 – 2008) - Etimesgut Military Hospital/Ankara

    (2011 – 2013) - GATA Medical Faculty Hospital/Ankara

    (2013-2015) - GATA Haydarpasa Training Hospital/Istanbul

    (05.2015-09.10.2017) - May 2015-09.10.2017 - Süleymaniye Gynecology and Pediatrics Training and Research Hospital/Istanbul

    (07.2015 – 01.2016) - Suleymaniye Gynecology and Pediatrics Training and Research Hospital Pediatrics Administrative Responsibility/Istanbul

    01.2016 - 09.11.2017 - Suleymaniye Gynecology and Pediatrics Training and Research Hospital Pediatric Clinic Education Responsibility / Istanbul

    (03.03.2016 - 30.10.2017) - Süleymaniye Gynecology and Pediatrics Training and Research Hospital Management

    (2017-2020) - Istinye University Faculty of Medicine Faculty Member

    (2020-Present) - Istanbul Aydın University Faculty of Medicine Faculty Member

    (20.10.2020-Present) - Head of Department of Child Health and Diseases, Faculty of Medicine, Istanbul Aydın University

     

    Courses and Certificates

    2001 - Flight Doctor Course

    2010 - Project Management Training Course

    2013 - Basic Epidemiology course

    2018 - Trainer Training Course

     

    Professional Memberships

    Pediatric Endocrinology and Diabetes Association

    European Society of Pediatric Endocrinology (ESPE)

    Istanbul Medical Chamber

     

    Awards

    İhsan Turan, Ian Hutchins, Bülent Hacıhamdioğlu, Leman Damla Kotan, Fatih Gürbüz, Mehmet Taştan, Ayça Ulubay, Eda Mengen, Bilgin Yüksel, Susan Wray, Ali Kemal Topaloğlu. CCDC141 Mutation in idiopathic hypogonadotropic hypogonadism. XVI. First Prize in Oral Presentation at the National Pediatric Endocrine and Diabetes Congress.

     

    Bülent Hacıhamdioğlu, Gönül Öçal, Merih Berberoğlu, ZeynepŞıklar, Ercan Tutar, Suat Fitöz, Gökhan Nergizoğlu, Şenay Savaş Erdeve, Emine Çamtosun. Control of premature microvascular aging and cardiovascular performance in obese adolescents. XVI. was held in Samsun on 6-10 November 2012. Second Prize in Oral Presentation at the National Pediatric Endocrine and Diabetes Congress.

     

    Z. Siklar, G. Ocal, M. Berberoglu, B. Hacıhamdioğlu, Ş. Savas Erdeve, Y. Egin, N. Akar. Control of hypercoagulability caused by obesity in children with endothelial microparticle level and thrombin generation test, and the relationship between risk and metabolic parameters. First Prize in Oral Presentation at the 55th Turkish National Pediatrics Congress held in Antalya on 12-16 October 2011

     

    Z. Şıklar, V. Topçu, P. Kocaay, M. Berberoğlu, B. Hacıhamdioğlu, S.S. Erdeve, H.R. Ilgin, A. Tükün, G. Öcal. Clinical Characteristics of Our Cases with Mutation in the Androgen Receptor Gene. XVI. was held in Samsun on 6-10 November 2012. First Prize in Oral Presentation at the National Pediatric Endocrine and Diabetes Congress.

  • 続きを読む
免疫療法
$3,500 - $3,500
情報

Philipp Riss

  • 4.6 優秀 172 レビュー
  • 21年の経験
  • 認定:
  • オーストリア, ウィーン, Wiener Privatklinik
  • Univ. Prof. Dr. Philipp Rissは、オーストリアの代表的な内分泌および一般外科医で、甲状腺、副甲状腺、および副腎の手術における専門性および内分泌腫瘍学に関する研究で国際的に認識されています。彼の正確な外科技術とエビデンスに基づいたアプローチは、彼をオーストリアの内分泌および代謝外科の最も尊敬される権威の一人にしました。

    彼はウィーン大学で医学を学び、1990年代に卒業し、ウィーン医科大学一般および臓器外科のレジデントを終えました。キャリアの初期において、彼は内分泌障害の外科的治療に特化し、代謝およびホルモン調節の知識を高度な低侵襲手術技術と組み合わせました。

         1990年代 – ウィーン大学での医学研究と外科訓練を完了。

         2000年代内分泌および代謝外科を専門とし、甲状腺摘出術、副甲状腺切除術、および副腎手術を実施。

         2010年代ウィーン医科大学の外科准教授に任命され、甲状腺がん、副甲状腺機能亢進症、内分泌腫瘍管理に関する研究を進める。

         今日ウィーン私立クリニックおよびウィーン総合病院(AKH)でシニアコンサルタントとして勤務し、内分泌腫瘍学、ホルモン関連疾患、精密外科療法に注力。

    Prof. Rissは、甲状腺および副甲状腺障害、内分泌腫瘍の生物学、術後の結果に関して広範で出版しており、内分泌外科における現在のヨーロッパ標準の形成に貢献しています。また、学術教育および国際外科協力に深く関与し、次世代の内分泌外科医を指導しています。

    正確な技術、科学的厳格さ、そして患者への共感で知られるProf. Rissは、内分泌および代謝外科における最高レベルの卓越性を象徴しており、精密さとケアが長期的な結果を決定します。

  • 続きを読む
診察
お問い合わせください
情報

Anton Luger

  • 4.6 優秀 172 レビュー
  • 46年の経験
  • 認定:
  • オーストリア, ウィーン, Wiener Privatklinik
  • ユニヴァーシティ・プロフェッサー ドクター アントン・ルガーは、オーストリアにおける 内分泌学、糖尿病学、代謝疾患の第一人者であり、内科医学での画期的な研究とリーダーシップで広く認識されています。彼の数十年にわたるキャリアは、オーストリアおよび国際的な臨床実践と学術医学の双方に影響を与えてきました。

    彼はウィーン大学で医学を学び、1970年代に学位を取得、その後ウィーン総合病院(AKH)で 内科医学および内分泌学を専門としました。ホルモンおよび代謝調節に対する彼の初期の興味は、糖尿病、下垂体および甲状腺疾患、そして神経内分泌腫瘍の研究に彼を導きました。

          1970年代 – ウィーン大学での医学研究を修了し、内科医学のレジデンシーを開始しました。

          1980年代内分泌学および糖尿病学を専門とし、ホルモン調節と代謝研究に焦点を当てました。

          1990年代 – ウィーン医科大学にて 内分泌代謝学部の教授および部長に任命され、ヨーロッパで最も進んだホルモン障害センターの一つを率いています。

          2000年代–2010年代 – 糖尿病管理、下垂体および副腎疾患、および革新的なホルモン療法について幅広く出版し、多数の国際臨床試験に貢献しました。

         現在ウィーナー私立クリニックの上級顧問として勤務し、研究、教育、若手医師の指導に積極的に関与しています。

    ルガー教授の臨床専門は、糖尿病、甲状腺および下垂体疾患、肥満、骨粗鬆症に加え、稀な内分泌シンドロームにも及びます。彼の業績は、オーストリアにおける現代のホルモン療法および糖尿病管理の発展に大きな影響を与えました。

    学問的な卓越性と患者中心のケアへの献身で知られるルガー教授は、科学的な精密さと深い共感を兼ね備え、最新の医学知識に基づいた個別のアプローチを患者一人ひとりに確実に提供しています。彼の貢献は、ヨーロッパの指導的な内分泌学者の一人として国際的に認められています。

  • 続きを読む
診察
お問い合わせください
情報

Yusuf Acikgoz

  • 4.9 優秀 8 レビュー
  • 10年の経験
  • トルコ, アンカラ, Lokman Hekim University Ankara Hospital
  • Associate Professor Dr. Yusuf AÇIKGÖZ
    Specialization: Medical Oncology

    Education:

    • 2004-2011: İnönü University Faculty of Medicine
    • 2011-2016: Ankara Numune Training and Research Hospital, Internal Medicine
    • 2017-2022: Health Sciences University, Medical Oncology

    Professional Experience:

    • 2016-2017: Bingöl City Hospital, Internal Medicine
    • 2021-2022: Health Sciences University, Medical Oncology
    • 2022-2023: Kastamonu Education and Research Hospital, Medical Oncology
    • 2023-2024: Ohio State University, Medical Oncology
    • 2024-Present: Lokman Hekim University, Medical Oncology, Ankara Hospital

    Clinical Trials, Courses, Certifications:

    Clinical Trials:

    • 2017-2021: Phase III, CheckMate-649 Study (Assistant Investigator)
    • 2022-Present: Phase III, Fortitude-101 Study (Assistant Investigator)

    Courses:

    • 2018: Medicres Basic and Advanced Biostatistics Training Program (ongoing), Istanbul-Vienna
    • 2019: Immuno-Oncology Education Course, March 1-2, 2019, Vienna, Central European Cooperative Oncology Group (CECOG)
    • 2018: Good Clinical Practice Certification, April 7-8, 2018, Ankara, Health Sciences University
    • 2017: Basic Oncology Training Program, November 25-26, 2017, Adana, Clinical Oncology Society
    • 2016: Basic Ultrasonography Course (10 hours theoretical + 10 hours practical), September 24-25, 2016, Ankara, Turkish Emergency Medicine Association

    Certifications:

    • Ongoing: ECFMG Certification
    • 2024: CITI Responsible Conduct of Research (The Ohio State University)
    • 2024: CITI IACUC-Laboratory Animal Research (The Ohio State University)
    • 2024: CITI Human Subjects Protection (The Ohio State University)
    • 2024: CITI Good Clinical Practice (The Ohio State University)
    • 2023: Occupational English Test (OET)
    • 2019: International English Language Testing System (IELTS), Total Score: 6.5, May 26, 2019, Ankara, British Council
    • 2017: USMLE Step 2 CK Exam; Score: 244, February 7, 2017
    • 2016: USMLE Step 1 Exam; Score: 215, August 25, 2016

    Memberships:

    • American Society of Clinical Oncology (ASCO) - 2022
    • Turkish Society of Medical Oncology - 2020
  • 続きを読む
肺癌手術
$10,940 - $16,410
高周波焼灼術
$5,470 - $10,390
ダビンチ前立腺全摘術
$10,120 - $11,760
情報

Lee Ji Hyun

  • 5 優秀 4 レビュー
  • 47年の経験
  • 大韓民国, 仁川, JIAN HEALTH PROMOTION CENTER
  • Lee Ji Hyun医師は、乳腺・甲状腺外科医です。Lee Ji HyunはNaeun Hospitalにて乳腺・甲状腺外科部門を統括しています。専門領域:乳腺良性疾患、乳癌、腫瘍外科。その他の専門:甲状腺良性疾患、甲状腺癌、副甲状腺疾患。専門技術:マンモトーム処置、腋窩リンパ節手術、乳腺・甲状腺超音波検査。

    学歴および研修歴:延世大学医科大学卒業。延世大学Severance病院にて一般外科インターンおよびレジデント研修修了。日本がん研究所附属病院にて短期臨床研修を修了。

    主な職歴:Incheon Christian Hospital一般外科部長、Cheil Hospital一般外科専門医。Samsung Cheil Hospital乳腺センター長および外科部長。Cheil Hospital一般外科部長および診療副院長。CHA大学CHA江南メディカルセンター外科非常勤教授。Daejeong Hospital一般外科部長。

  • 続きを読む
診察
お問い合わせください
情報

Esra Demir

  • 5 優秀 3 レビュー
  • 17年の経験
  • トルコ, イスタンブール, Medipol Acibadem District Hospital
  • Education:

    • Degree: Faculty of Medicine, Trakya University, 2009
    • Medical Specialty: Internal Medicine, Bakırköy Dr. Sadi Konuk Training and Research Hospital, 2010-2014
    • Specialist Doctor: Internal Medicine, Kanuni Sultan Süleyman Training and Research Hospital, 2014-2019
    • Specialist Doctor: Internal Medicine, Turkish Hospital Internal Medicine Clinic, Qatar, 2019-2020
    • Specialist Doctor: Internal Medicine, Istanbul Medipol University Hospital Mega Hospital Internal Medicine Department, 2020-2024
    • Associate Professor Doctor: Internal Medicine, Istanbul Medipol University Medipol Acıbadem Regional Hospital, 2024-Present.

    Roles in Projects:

    Sub investigator (Assistant Researcher) in the SOUL Study: Cardiovascular Outcome Research of Semaglutide in Type 2 Diabetic Patients, approved by the Turkish Medicines and Medical Devices Agency on May 22, 2019.

    Sub investigator (Assistant Researcher) in the international study “SCALE™ Insulin”: Efficacy and Safety of Liraglutide 3.0 mg in Overweight or Obese Patients with Type 2 Diabetes Treated with Basal Insulin (Study Code: NN8022-4272), conducted by Novo Nordisk A.Ş.

    Subinvestigator (Assistant Researcher) in the international study NN5401-4266 StepByStep Intensification conducted by Novo Nordisk.

    Assistant Researcher in the study "A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (SUSTAIN 11)" (2019-2020).

    Assistant Researcher in the PIONEER 1 study: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.

  • 続きを読む
診察
お問い合わせください
情報

Fatma Ela Keskin

  • 5 優秀 55 レビュー
  • 17年の経験
  • トルコ, イスタンブール, Istanbul Florence Nightingale Hospital
診察
お問い合わせください
情報

Viktor Alexander Krol

  • 4 良い 1 レビュー
  • 26年の経験
  • ドイツ, デュッセルドルフ, St. Martinus-Krankenhaus Düsseldorf
  • ヴィクトル・アレクサンダー・クロル医師 — マルティヌス病院 消化器内科・内科・肥満治療センター長

     

    ヴィクトル・アレクサンダー・クロル医師は、消化器内科および内科を統括する高度な専門医です。長年にわたる豊富な経験と深い専門知識を持つクロル医師は、卓越した専門家として広く認められており、患者一人ひとりに対して包括的な治療と個別化されたアプローチを提供しています。消化管疾患、代謝疾患、ならびに循環器疾患および呼吸器疾患の診断・治療において、最新の手法を積極的に活用しています。

     

    クロル医師はまた、マルティヌス病院における認定肥満治療センターの責任者も務めており、同センターでは肥満に対する外科的および内視鏡的治療が提供されています。このセンターでは、肥満症(アディポシタス)の診断と治療に最先端の技術が導入されており、肥満外科手術(バリアトリック手術)、内視鏡的減量療法、さらには各種肥満病期の患者を対象とした専門的プログラムなどが実施されています。同センターは高い水準に基づいて認定を受けており、この重篤な疾患の治療において優れた実績を上げています。

     

    クロル医師が率いる消化器内科では、胃・腸・肝臓・膵臓・胆嚢の疾患の診断および治療を行っています。内視鏡的処置、超音波検査をはじめとする幅広い最新の診断技術が活用されています。

     

    内科部門は、循環器科、糖尿病科、感染症科、ならびに呼吸器疾患・腎疾患の治療を含む広範な疾患領域を対象としています。クロル医師とそのチームは、最先端の医療手法を用いた包括的な治療アプローチを提供しています。

     

    高い専門性と患者一人ひとりへの真摯な姿勢により、クロル医師は同僚および患者から深い尊敬を集めています。

  • 続きを読む
診察
お問い合わせください
情報

Ali Saklamaz

  • 31年の経験
  • トルコ, イズミル, Medicalpoint International Hospital
  •  

    Education and Expertise

    • 1989 BORNOVA ANATOLIAN HIGH SCHOOL
    • UNDERGRADUATE DEGREE 1995 EGE UNIVERSITY/ FACULTY OF MEDICINE
    • SPECIALIZATION IN MEDICINE 2001 DOKUZ EYLÜL UNIVERSITY/MEDICAL FACULTY INTERNAL MEDICINE DEPARTMENT
    • MEDICAL SPECIALIST 2005 DOKUZ EYLÜL UNIVERSITY FACULTY OF MEDICINE ENDOCRINE AND METABOLISM DISEASES

     

     

    Biography

    Our doctor admits patients aged or older than 15.

    Medical Education

    School of Medicine, Ege University

    Medical Residency

    Department of Internal Medicine, School of Medicine, Dokuz Eylül University

    Department of Endocrinology, School of Medicine, Dokuz Eylül University

    Areas of Interest

    Diabetes Mellitus

    Thyroid Diseases

    Pituitary Diseases

    Hirsutism

    Osteoporosis

    Membership

    Turkish Society of Endocrinology and Metabolism

    Experience

    • 2005-2009 Private Western Anatolia Central Hospital
    • 2009-2011 Private Healing Hospital
    • 2011-2016 Private Izmir Sifa University
    • 2016-2023 Izmir Medical Point Hospital

    Professional Memberships

    • Turkish Medical Association
    • Turkish Endocrinology and Metabolism Association

     

  • 続きを読む
診察
お問い合わせください
情報

Nail Paksoy

  • 4.5 良い 2 レビュー
  • 15年の経験
  • 認定:
  • トルコ, イスタンブール, Medipol Bahçelievler Hospital

  • PROFESSIONAL EXPERIENCE

    2011-2012
    Erzurum Koprukoyu State Hospital
    Department: General Medicine

    2012-2017
    Istanbul University Cerrahpaşa Medical Faculty
    Department: Internal Medicine

    06/2017-10/2017
    Istanbul Gaziosmanpasa Taksim Training and Research Hospital
    Department: Internal Medicine

    10/2017-11/2018
    Istanbul University Istanbul Medical Faculty
    Department: Allergy and Immunology Fellowship

    2018/2022
    Istanbul University Oncology Institute
    Department: Medical Oncology Fellowship

    2022-2023
    Tekirdag City Hospital
    Department: Medical Oncology Specialist

    2023-present
    Istanbul Medipol University Medipol Bahcelievler Private Hospital
    Department: Medical Oncology Assoc. Prof.

     

    EDUCATION

    2005-2011
    Medical Education
    Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

    2012-2017
    Internal Medicine
    Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

    2017-2018
    Allergy-Immunology Fellowship
    Istanbul University Istanbul Medical Faculty
    Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

    2018-2022
    Medical Oncology Fellowship
    Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

    2022
    ESMO Board Certification in Medical Oncology
    10th September 2022 in Paris, France.

    2023
    Medical Oncology Assoc. Prof.
    Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

     

    INTERNATIONAL CLINICAL TRIALS:

    1. Astefania - ROCHE

    • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
    • Role: Subinvestigator

    2. PFİZER

    • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
    • Role: Subinvestigator

    3. RECITE - AMGEN

    • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
    • Role: Subinvestigator

    4. NAVIGATE - BAYER

    • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    • Role: Subinvestigator

    5. RUBY - Tesaro (PRA)

    • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
    • Role: Subinvestigator

    6. ENGOT-ov43/GOG-3036 - MSD

    • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
    • Role: Subinvestigator

    7. ASTRA ZENECA

    • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
    • Role: Subinvestigator

    8. ROSY-O - ASTRA ZENECA

    • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
    • Role: Subinvestigator
    •  

    INTERNATIONAL PUBLICATIONS

    I. Published journal articles indexed by SCI, SSCI, and AHCI

    Weekly Paclitaxel in Classic Kaposi Sarcoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
    • Journal: Medicine, 102(5)

    Carboplatin Desensitization in Ovarian Carcinoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
    • Journal: Medicine, 101(45), e31726

    High-Dose Chemotherapy for Ewing’s Sarcoma

    • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
    • Journal: Medicine, 101(49), e32213

    Multidrug Refractory TFE3(+) Renal Cell Carcinoma

    • Authors: Paksoy, Nail, et al.
    • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

    Crizotinib Efficacy in NSCLC with MET Alterations

    • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
    • Journal: Medicine, 101(50), e32368

    Clinicopathological Features in ALK Mutant NSCLC

    • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
    • Journal: Medicine, 101(34)

    PSMA-Based Tumor Burden in Prostate Cancer

    • Authors: HAS SIMSEK, Duygu, et al.
    • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

    Atezolizumab in Metastatic Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: European Urology Focus, 2021, 7.5: 1061-1066

    Pulmonary Sarcomatoid Carcinoma

    • Authors: FERHATOGLU, Ferhat, et al.
    • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

    Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

    Atezolizumab with Chemotherapy in Small Cell Lung Cancer

    • Authors: GÜRBÜZ, Mustafa, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

    FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

    • Authors: AY, Seval, et al.
    • Journal: Journal of Chemotherapy, 2022, 1-7

    Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

    • Authors: CIL, Ibrahim, et al.
    • Journal: Tumori Journal, 2022, 108.1: 19-25

    Real-Life Efficacy of Osimertinib in Advanced NSCLC

    • Authors: HIZAL, Mutlu, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

    ALK-Positive Cells Percentage and Alectinib Efficacy

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
    • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

    Real-World Data on Alectinib in ALK-Positive NSCLC

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
    • Journal: Future Oncology, 18(23), 2573-2582

    Prognostic Factors in Metastatic RCC with T790M Mutation

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

    • Authors: DEMIR, Semra, et al.
    • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

    Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

    • Authors: ÖZDEMIR, Seçil Kepil, et al.
    • Journal: Allergy, 2019, 74.6: 1187-1190

    Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

    • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
    • Journal: The Oncologist, oyad257

    Subsequent Treatments in Hormone-Positive Breast Cancer Progression

    • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
    • Journal: BMC cancer, 23(1), 192

    Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
    • Journal: Scientific Reports, 13(1), 8779

    Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
    • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

    Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

    • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
    • Journal: European Journal of Breast Health, 19(2), 128

    Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

    • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
    • Journal: Future Oncology, 19(10), 727-736

    Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

    • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
    • Journal: [Not specified]

    Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

    • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
    • Journal: Medicine, 102(39), e35383

    Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

    • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
    • Journal: Medicine, 102(41), e35245

    Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

    Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

    Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

    Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

    Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

    Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

    Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

    Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

    Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

    Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

    Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

    Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

    Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

     

    Thesis:

    Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

    International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

    Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

    • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

    Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

    • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

    Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

    • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

    Efficacy of temozolomide in pretreated patients with metastatic sarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

    • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

    • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

    Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

    • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

    Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

    • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

    Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

    • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

     

     

  • 続きを読む
肺癌手術
$15,000 - $20,000
脊髄腫瘍摘出術
$12,000 - $17,000
乳がん放射線治療
$4,000 - $6,000
情報

tian Jian Qing

  • 26年の経験
  • 中国, 厦門 (シャーメン), Xiamen Humanity Hospital
  • Dr Tian Jian Qing is Director of Endocrinology and a Senior Expert in Endocrine & Metabolic Therapeutics. He has over 20 years of clinical experience. He previously worked at Xinjiang Military Command General Hospital and at Renji Hospital, Shanghai Jiao Tong University.

    He has published over 20 SCI and Chinese core journal papers. He is chief editor of four monographs and co-editor of four others. He has produced more than 1,000 health education materials. His clinical focus includes endocrine and metabolic disorders, dysglycemia, dyslipidemia, and hypertension. He also treats weight, thyroid, and bone diseases, menopausal syndrome, PCOS, and gestational diabetes and thyroid disorders.

    He holds Standing Council and Committee roles in the Fujian Cross-Strait Medicine & Health Exchange Association and the Fujian Primary Health Association. He also serves in the Xiamen Medical Association and the Xiamen Medical Doctor Association. He is Deputy Chair of the Diabetes Branch of the Xiamen Medical Association.

  • 続きを読む
診察
お問い合わせください
情報

Muhammed Mustafa Atci

  • 5 優秀 1 レビュー
  • 15年の経験
  • トルコ, イスタンブール, İstinye University Liv Hospital Topkapı
  • Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

    He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

    Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

  • 続きを読む
診察
お問い合わせください
情報

Atakan Topcu

  • 5 優秀 3 レビュー
  • 13年の経験
  • トルコ, イスタンブール, Medipol Acibadem District Hospital
  • Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

    He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

    Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

  • 続きを読む
診察
お問い合わせください
情報

Hakan Duger

  • 4.5 良い 6 レビュー
  • 14年の経験
  • トルコ, アンタルヤ, Medical Park Antalya Hospital Complex
  • Dr. Hakan Duger is a specialist in Endocrinology and Metabolic Diseases. He has worked at Gaziantep Özel Defa Life Hospital since 2023. He previously served at Kilis Prof. Dr. Alaeddin Yavaşca State Hospital from 2021 to 2023.

    Education and training: Gazi University Faculty of Medicine (2006–2012). Internal Medicine residency at Uludağ University (2012–2017). Endocrinology and Metabolic Diseases training at Ankara Numune Training and Research Hospital (2017–2018) and Ankara Dışkapı Yıldırım Beyazıt Training and Research Hospital (2018–2021). He also served as an Internal Medicine specialist at Şanlıurfa Mehmet Akif İnan Training and Research Hospital (2017–2019).

    Professional memberships: Turkish Medical Association. Turkish Society of Endocrinology and Metabolism. Turkish Diabetes Association. Clinical Endocrinology and Diabetes Association.

  • 続きを読む
腎摘出術
$8,000 - $9,500
乳房切除術
$7,500 - $7,500
情報

Ferit Çelik

  • 16年の経験
  • トルコ, イズミル, Medicalpoint International Hospital
  • Education and Expertise

    • 2023 BAKIRÇAY UNIVERSITY ÇİĞLİ TRAINING AND RESEARCH HOSPITAL (ASSOCIATE PROFESSOR)
    • 2021 EGE UNIVERSITY FACULTY OF MEDICINE GASTROENTEROLOGY DEPARTMENT
    • 2017 EGE UNIVERSITY INTERNAL MEDICINE DEPARTMENT
    • 2010 EGE UNIVERSITY FACULTY OF MEDICINE

    Diseases

    • Liver Diseases
    • Digestive System Diseases

    Treatment Methods

    • Endoscopy
    • Endoscopic mucosal resection – EMR
    • Endoscopic Obesity Treatment (Intragastric Botox, Intragastric Balloon)
    • Endoscopic Polypectomy
    • Endoscopic Retrograde Cholangio Pancreatography (ERCP)
    • Liver Transplant
    • Colonoscopy
    • Peroral Cholangioscopy

    Experience

    • Diyarbakir 112 Emergency Health Services Chief Physician (2010-2011)
    • Ege University Faculty of Medicine, Department of Internal Medicine (2012-2017)
    • Ayvalik State Hospital (2017-2018)
    • Ege University Faculty of Medicine, Department of Gastroenterology (2018-2021)
    • Burdur State Hospital (2021-2022)
    • Bakırçay University Çiğli Training and Research Hospital (2022-2024)

    Professional Memberships

    • 1.Turkish Gastroenterology Association (ERCP working group)
    • 2. Turkish Liver Research Association
    • 3. Turkish Medical Association
  • 続きを読む
診察
お問い合わせください
情報

Mehmet Fatih Kilicli

  • 5 優秀 3 レビュー
  • 34年の経験
  • トルコ, イスタンブール, Medipol Acibadem District Hospital
  • Education and Experience

    • 1992 - 1998, Gaziantep University, Faculty of Medicine
    • 2002 – 2015, Cumhuriyet University, Faculty of Medicine, Department of Internal Medicine
    • 2015 – 2024, Bağcılar Medipol Mega University Hospital
    • 2024 – Present, Medipol Acıbadem Hospital
  • 続きを読む
診察
お問い合わせください
情報

Zuhal Cakmak Peksen

  • 5 優秀 1 レビュー
  • 13年の経験
  • トルコ, イスタンブール, İstinye University Liv Hospital Topkapı
  • Dr. Zuhal Cakmak Peksen is a Family Medicine Specialist since 2017. She earned her MD from Çukurova University in 2010. She completed specialty training at Yüzüncü Yıl University between 2013 and 2017. She is currently studying for a bachelor’s degree in Health Management at Anadolu University (2024–present).

    She has 15 years of clinical practice (2010–2025) across 8 institutions. Her experience includes research in Family Medicine (2013–2017) and work at several Family Health Centers. Since 2020, she has served at TOKİ Avrupa Family Health Center in Gaziosmanpaşa, Istanbul.

  • 続きを読む
診察
お問い合わせください
情報

Tulay Omma

  • 5 優秀 1 レビュー
  • 24年の経験
  • トルコ, アンカラ, Lokman Hekim Akay Hospital
  • Dr. Tülay Omma, Associate Professor

    Specialization: Endocrinology and Metabolic Diseases

    Academic Background

    • Medical Education: İnönü University, Faculty of Medicine (English Program), 1994–2001.
    • Internal Medicine Residency: Haseki Training and Research Hospital, 2004–2010.
    • Subspecialty in Endocrinology and Metabolism: Ankara Training and Research Hospital, 2013–2017.

    Professional Experience

    • Clinical Expertise: 
      • General Practitioner with administrative responsibilities, 2002–2004.
      • Specialist in Internal Medicine during mandatory service, 2010–2013.
      • Endocrinologist and Metabolic Disease Specialist at Ankara Training and Research Hospital (2017–2023).
      • Earned the title of Associate Professor in 2023, reflecting her academic and clinical excellence.
        Lokman Hekim Health Group 2023 (present) 

    Scientific Contributions & Publications

    • Research Output: 
      • Published over 20 articles in peer-reviewed international journals, with a strong focus on diabetes, thyroid disorders, and polycystic ovary syndrome.
      • Delivered numerous oral presentations and posters at national and international conferences.
    • Citation Metrics: 
      • Total Citations: 166
      • H-index: 6
      • i10-index: 4

    Awards & Recognitions

    • Multiple prestigious accolades, including: 
      • Best Oral Presentation Award (2023): For groundbreaking research on COVID-19 vaccines and Graves’ Disease.
      • Best Poster Award (2021): For clinical insights into hypoparathyroidism in Turkey (HiPOPARATURK-NET Study).

    Professional Memberships & Certifications

    • Active member of leading organizations: 
      • European Society of Endocrinology (ESE) and its Young Endocrinologists & Scientists Committee (EYES).
      • Turkish Society of Endocrinology and Metabolism.
    • Completed numerous advanced training programs, including certifications in clinical trials, biostatistics, and thyroid ultrasonography.

    Clinical & Research Focus

    Dr. Omma’s expertise spans:

    • Diabetes management and its complications.
    • Advanced thyroid disease diagnosis and treatment.
    • Polycystic Ovary Syndrome (PCOS) and its metabolic implications.
    • Investigating the relationship between diet and endocrine/metabolic disorders.

     

     

     

     

  • 続きを読む
診察
お問い合わせください
情報

Havva Asuman Yavuz

  • 4.5 良い 6 レビュー
  • 28年の経験
  • トルコ, アンタルヤ, Medical Park Antalya Hospital Complex
  • Education and Specialization

    • Hacettepe University Faculty of Medicine – English Medical Education
    • Akdeniz University Faculty of Medicine – Internal Medicine – Residency
    • Akdeniz University Hospital – Nephrology – Subspecialty Training
    • San Bortolo Hospital, Vicenza, Italy – Critical Care Nephrology and Transplantation – Fellowship
    • Hacettepe University Faculty of Medicine – Associate Professorship

    Professional Memberships

    1. Turkish Society of Nephrology (TND)
    2. European Society of Nephrology (ERA-EDTA)
    3. Middle East Society of Organ Transplantation (MESOT)
    4. International Society of Nephrology (ISN)
  • 続きを読む
腎摘出術
$8,000 - $9,500
乳房切除術
$7,500 - $7,500
情報

Mustafa Serkan Alemdar

  • 4.5 良い 6 レビュー
  • 20年の経験
  • トルコ, アンタルヤ, Medical Park Antalya Hospital Complex
  • Education and Specialization

    • 2006: Kocaeli University Faculty of Medicine
    • 2014: Akdeniz University Faculty of Medicine, Internal Medicine
    • 2018: Akdeniz University Faculty of Medicine, Medical Oncology

    Experience

    • 2006 - 2008: Konya Derebucak District Hospital
    • 2009 - 2015: Akdeniz University Hospital
    • 2015: Antalya Kaş State Hospital
    • 2015 - 2016: İnönü University Faculty of Medicine
    • 2016 - 2021: Akdeniz University Hospital
    • 2021 - 2023: Antalya Training and Research Hospital
  • 続きを読む
腎摘出術
$8,000 - $9,500
乳房切除術
$7,500 - $7,500
情報